ATR and B-cell chronic lymphocytic leukemia: Among them, ceralasertib (AZD6738), the oral ATR inhibitor, has been used in clinical trials as both monotherapy and combination therapy strategies, including chronic lymphocytic leukemia (CLL) [21], mantle cell lymphoma [22], gastric cancer [23], and breast cancer [24].